Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 17/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
| ▸ | CCKBR | P32239 | 5/20 | 0.51 |
| ▸ | CCKAR | P32238 | 4/20 | 0.51 |
| ▸ | TFPI | P10646 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663842 | 0.94 | TFPI (0.57) | TFPI | |
| SCHEMBL30273402 | 0.89 | OPRD1 (0.53) | OPRD1OPRM1OPRK1CCKBRCCKAR | |
| SCHEMBL29590452 | 0.89 | OPRM1 (0.55) | OPRD1OPRM1OPRK1TFPI | |
| SCHEMBL29376413 | 0.87 | TFPI (0.56) | OPRD1OPRM1OPRK1TFPI | |
| SCHEMBL31243881 | 0.87 | OPRD1 (0.60) | OPRD1OPRM1OPRK1OPRL1 | |
| Acetic Acid SCHEMBL29981808 | 0.86 | LNPEP (0.53) | OPRD1OPRM1OPRK1CCKBRCCKAR | |
| SCHEMBL31257066 | 0.86 | OPRD1 (0.61) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30271263 | 0.85 | NPY4R (0.61) | OPRD1OPRK1 | |
| SCHEMBL31243856 | 0.85 | OPRD1 (0.70) | OPRD1OPRM1OPRK1CCKBRCCKAR | |
| SCHEMBL30900788 | 0.85 | OPRD1 (0.60) | OPRD1OPRM1OPRK1CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12214015-B2 | Use of c-type natriuretic peptide variants to treat osteoarthritis | BIOMARIN PHARMACEUTICAL INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20220160836-A1 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BIOMARIN PHARMACEUTICAL INC. | 2022-05-26 | — | — | US | disclosed |